Acinetobacter baumani and Pseudomonas aeruginosa drug susceptibility after bacteriological analysis of sputum in patients mechanically ventilated in ICUSource: Eur Respir J 2003; 22: Suppl. 45, 450s Year: 2003
Community-acquired pneumonia due to multidrug and non-multidrug resistant pseudomonas aeruginosa Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016
Acinetobacter baumanii as a severity marker in a respiratory ICUSource: Eur Respir J 2006; 28: Suppl. 50, 786s Year: 2006
Carbapenems for the treatment of immunocompetent adult patients with nosocomial pneumonia Source: Eur Respir J 2007; 29: 548-560 Year: 2007
Potential treatment for nosocomial respiratory strains of extreme drug resistant acinetobacter baumanii Source: Eur Respir J 2007; 30: Suppl. 51, 410s Year: 2007
Prognosis of Acinetobacter baumannii bacteraemia in a respiratory ICU: 10 years‘ experience Source: Eur Respir J 2005; 26: Suppl. 49, 222s Year: 2005
Acinetobacter baumannii infection and colonization among pediatric patients in pediatric ICU and other ICUs Source: International Congress 2018 – Neonatology and paediatric intensive care Year: 2018
The mortality of Acinetobacter baumanni infection in intensive care unit Source: Annual Congress 2012 - Infections and sepsis in the ICU Year: 2012
Antibiotic sensitivity of pseudomonas aeroginosa isolates of respiratory secretions taken from ICU patients of the NRITLD Source: Eur Respir J 2004; 24: Suppl. 48, 641s Year: 2004
Clinical outcomes of tigecycline in the treatment of critically ill patients with multidrug-resistant Acinetobactor baumannii infection Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections Year: 2011
Factors associated with mortality in ventilator associated pneumonia of multidrug resistant acinetobacter baumannii Source: Annual Congress 2013 –Antibiotics, resistance and vaccines Year: 2013
Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: diagnosis, incidence and predictors Source: Eur Respir J 2010; 35: 598-615 Year: 2010
Acinetobacter baumanii and Stenotrophomonas maltophilia are associated with lower airway infections in tracheostomised children and young adults. Source: International Congress 2017 – New insights into paediatric respiratory infections Year: 2017
Association of acinetobacter baumannii respiratory isolates with hospital outcomes in ventilated patients Source: Eur Respir J 2006; 28: Suppl. 50, 785s Year: 2006
Inhaled colistin on Acinetobacter baumannii treatment Source: Annual Congress 2012 - Infections and sepsis in the ICU Year: 2012
Activity of N-acetylcysteine in combination with colistin against a collection of colistin resistant Acinetobacter baumannii clinical isolates Source: International Congress 2017 – How can microbiology and translational research help physicians? Year: 2017
Multidrug resistant acinetobacter baumanii pneumonia: Mortality analysis and comparison of intravenous versus aerosolized therapy Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014
Multidrug-resistant bacteria in community-acquired pneumonia Source: International Congress 2017 – PG17 Infectious disease challenges in community-acquired pneumonia and tuberculosis: improving your clinical practice Year: 2017
Direct LAMP assay from clinical sample for carbapenem resistant A. baumannii Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections Year: 2014
Multidrug resistant acinetobacter baumannii in ventilator associated pneumonia: Prevalence and predictors of mortality Source: International Congress 2014 – ICU outcomes, sepsis and infections Year: 2014